Evoke Pharma Inc. (EVOK), in collaboration with Eversana Life Science Services, LLC., has announced statistically significant data from its study on Gimoti nasal spray. This study investigates Gimoti's potential as a supportive treatment for patients with diabetic gastroparesis who are also using Glucagon-like peptide-1 (GLP-1).
GLP-1 is a hormone crucial for regulating blood sugar levels and appetite. Diabetic gastroparesis, on the other hand, is a condition where gastric emptying is delayed due to nerve damage caused by prolonged high blood sugar levels.
The findings were recently shared at the 2024 annual meeting of the American College of Gastroenterology. The research compared healthcare resource utilization between patients treated with Gimoti and those using oral metoclopramide. Results indicated a reduction in medical intervention among those receiving Gimoti, with GLP-1 patients experiencing fewer healthcare visits overall.
As it stands, Evoke's stock is trading at $8.85, reflecting a significant increase of 72.50 percent on the Nasdaq.
